The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

The treatment regimen of rituximab, bendamustine, bortezomib, and dexamethasone demonstrated activity and a manageable safety profile as a first-line therapy for patients with mantle cell lymphoma aged 65 years or older, according to findings from a prospective, multicenter phase II study.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.